triiodothyronine has been researched along with Skin Neoplasms in 8 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Skin Neoplasms: Tumors or cancer of the SKIN.
Excerpt | Relevance | Reference |
---|---|---|
"Bexarotene-induced central hypothyroidism (CH), for which levothyroxine (LT4) replacement is recommended, has been shown to be caused by pituitary but not hypothalamic disorder experimentally, though the underlying mechanism in humans remains unclear." | 8.12 | Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. ( Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S, 2022) |
"Bexarotene-induced central hypothyroidism (CH), for which levothyroxine (LT4) replacement is recommended, has been shown to be caused by pituitary but not hypothalamic disorder experimentally, though the underlying mechanism in humans remains unclear." | 4.12 | Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. ( Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S, 2022) |
"Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs)." | 1.51 | Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. ( Fujii, T; Hishizawa, M; Inagaki, N; Kawaguchi-Sakita, N; Kim, YH; Kitamura, M; Kitawaki, T; Matsumoto, S; Nomura, M; Otsuka, A; Saito, R; Sakamori, Y; Sone, M; Taura, D; Yamasaki, T; Yamauchi, I; Yasoda, A, 2019) |
"Vitiligo is the most common pigmentation-related disorder worldwide." | 1.37 | Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. ( Alpay, K; Bahadır, S; Okten, A; Uncu, S; Yaylı, S, 2011) |
"Pancreatic cancer was induced by treatment with 40 mg/kg body wt N-nitrosobis-(2-oxopropyl)amine (BOP)." | 1.27 | Enhanced pancreatic and skin tumorigenesis in cabbage-fed hamsters and mice. ( Birt, DF; Bresnick, E; Pelling, JC; Pour, PM; Schweickert, L; Tibbels, MG, 1987) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (37.50) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Toi, N | 1 |
Kurajoh, M | 1 |
Miyaoka, D | 1 |
Nagata, Y | 1 |
Yamada, S | 1 |
Imanishi, Y | 1 |
Hayashi, D | 1 |
Tateishi, C | 1 |
Inaba, M | 1 |
Tsuruta, D | 1 |
Morita, A | 1 |
Emoto, M | 1 |
Yamauchi, I | 2 |
Sakane, Y | 1 |
Fukuda, Y | 1 |
Fujii, T | 2 |
Taura, D | 2 |
Hirata, M | 1 |
Hirota, K | 1 |
Ueda, Y | 1 |
Kanai, Y | 1 |
Yamashita, Y | 1 |
Kondo, E | 1 |
Sone, M | 2 |
Yasoda, A | 2 |
Inagaki, N | 2 |
Ansorge, C | 1 |
Seufert, J | 1 |
Meiss, F | 1 |
von Bubnoff, D | 1 |
Matsumoto, S | 1 |
Sakamori, Y | 1 |
Kim, YH | 1 |
Nomura, M | 1 |
Otsuka, A | 1 |
Yamasaki, T | 1 |
Saito, R | 1 |
Kitamura, M | 1 |
Kitawaki, T | 1 |
Hishizawa, M | 1 |
Kawaguchi-Sakita, N | 1 |
Uncu, S | 1 |
Yaylı, S | 1 |
Bahadır, S | 1 |
Okten, A | 1 |
Alpay, K | 1 |
SHERWIN-WEIDENREICH, R | 1 |
HERRMANN, F | 2 |
WEIDENREICH-SHERWIN, R | 1 |
Birt, DF | 1 |
Pelling, JC | 1 |
Pour, PM | 1 |
Tibbels, MG | 1 |
Schweickert, L | 1 |
Bresnick, E | 1 |
8 other studies available for triiodothyronine and Skin Neoplasms
Article | Year |
---|---|
Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients.
Topics: Bexarotene; Humans; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Retrospective Studies; Skin Neoplas | 2022 |
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lung Neoplasm | 2017 |
Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
Topics: Adult; Antineoplastic Agents, Immunological; Autoimmune Hypophysitis; Humans; Hydrocortisone; Hypopi | 2018 |
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxygluco | 2019 |
Relevance of autoimmune thyroiditis in children and adolescents with vitiligo.
Topics: Adolescent; Age of Onset; Autoantibodies; Child; Child, Preschool; Comorbidity; Female; Humans; Inci | 2011 |
Hair cycle and chemically induced epidermal carcinogenesis in mice receiving tri-iodothyronine. I. Findings after single application of 9,10-dimethyl-1,2-benzanthracene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Benz(a)Anthracenes; Carcinogenesis; Epidermis; Hair; Mice | 1963 |
HAIR CYCLE AND CHEMICALLY INDUCED EPIDERMAL CARCINOGENESIS IN MICE RECEIVING LIOTHYRONINE. II. FINDINGS AFTER MULTIPLE APPLICATIONS OF METHYLCHOLANTHRENE.
Topics: Animals; Carcinogenesis; Epidermis; Hair; Methylcholanthrene; Mice; Neoplasms; Neoplasms, Experiment | 1964 |
Enhanced pancreatic and skin tumorigenesis in cabbage-fed hamsters and mice.
Topics: Animals; Body Weight; Brassica; Cricetinae; Dietary Fats; Female; Gallbladder Neoplasms; Male; Mesoc | 1987 |